ANTX stock forecast, quote, news & analysis
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform... Show more
Why AN2 Therapeutics (ANTX) Is Up +223% in the Last 30 Days
Key Takeaways
- ANTX stock surged +223% over the last 30 days, driven by clinical advancements for epetraborole and a $40 million private placement financing.
- Over the past quarter, the stock rose +208%, reflecting positive momentum from pipeline progress in infectious diseases.
- Key catalysts include Phase 2 trial initiations for Mycobacterium abscessus lung disease and Polycythemia Vera, alongside Q4 financial results.
- Biotech sector sentiment and boron chemistry platform innovations bolstered investor interest in recent stock analysis.
- Recent Phase 2 trial start signals continued R&D momentum amid volatile price movement.
AN2 Therapeutics (ANTX) Company Overview and Market Position
AN2 Therapeutics, Inc. (ANTX) is a biopharmaceutical company specializing in novel small molecule therapeutics derived from its proprietary boron chemistry platform. Headquartered in Menlo Park, California, the firm focuses on underserved areas like infectious diseases, with lead candidate epetraborole in Phase 3 trials for non-tuberculous mycobacterial (NTM) lung disease and acute melioidosis. Additional pipeline assets include AN2-502998 for chronic Chagas disease in preclinical stages, plus programs in oncology.
AN2 operates in the competitive biotechnology industry, leveraging licensing deals with Anacor Pharmaceuticals, Brii Biosciences, and GSK for tuberculosis therapies. Its fundamentals—emphasizing boron-based inhibitors—position it well for breakthroughs in resistant infections, explaining recent stock price resilience amid clinical milestones that drive market trends.
AN2 Therapeutics (ANTX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ANTX stock climbed from approximately $1.06 to $3.42, marking a +223% gain. The movement was highly volatile and trend-driven, highlighted by multi-day surges exceeding 100% following key announcements, before modest pullbacks.
For the quarter, shares advanced +208% from around $1.11 to $3.42. Performance featured steady early gains accelerating into sharp rallies, characteristic of biotech stocks reacting to pipeline news, with range-bound periods interspersed by high-volume spikes.
What Drove ANTX Stock Price in the Last 30 Days
The 30-day rally stemmed primarily from pipeline catalysts. On March 3, AN2 announced plans to advance oral epetraborole into a Phase 2 study for Polycythemia Vera (PV), a blood disorder, sparking initial optimism. This was amplified on March 9 by a $40 million private placement financing, selling shares at $2.85 and warrants, providing runway for trials—shares doubled that day amid biggest-ever gains.
March 17 brought Q4 2025 results, reporting EPS of -$0.29 versus -$0.25 last year, but highlighting scientific progress. Option repricing on March 20 aided retention. The March 31 Phase 2 initiation for Mycobacterium abscessus lung disease sustained momentum, boosting sentiment in stock price analysis despite volatility.
What Drove ANTX Stock Performance Over the Last Quarter
Quarterly gains built on sustained narratives around epetraborole's expansion. Early January FDA clearance for a 90-patient investigator-initiated trial (IIT) in M. abscessus lung disease laid groundwork. January leadership adjustments and conference participation enhanced visibility.
Biotech industry trends favoring infectious disease innovators, coupled with AN2's boron platform differentiation, drew institutional interest like Commodore Capital's stake. Macro factors, including healthcare funding amid regulatory stability, supported cumulative impact, with financing and trial news as strongest drivers of price movement.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots from hundreds available, trading thousands of tickers across strategies like trend-following, mean reversion, and momentum plays. These bots vary in timeframe—from intraday to long-term—and performance metrics such as win rate, Sharpe ratio, and maximum drawdown. Curated for relevance and real-time results, the section highlights bots excelling in current market trends, offering transparency via backtested and live data. Explore these tools to enhance your stock analysis and automate trading decisions.
ANTX Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor upcoming Phase 2 data readouts for epetraborole in PV and M. abscessus lung disease, alongside progress in NTM Phase 3 trials. Q1 2026 earnings and cash burn post-financing will gauge financial health.
Industry trends in infectious diseases, potential partnerships expanding the boron platform, and macroeconomic shifts like biotech funding or FDA decisions remain key. Risks include trial setbacks; catalysts could involve oncology updates or regulatory milestones affecting sentiment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
ANTX's RSI Oscillator peaks and leaves overbought zone
The 10-day RSI Indicator for ANTX moved out of overbought territory on March 18, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 instances where the indicator moved out of the overbought zone. In of the 21 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for ANTX turned negative on March 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 27 similar instances when the indicator turned negative. In of the 27 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ANTX entered a downward trend on April 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 49 cases where ANTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on April 17, 2026. You may want to consider a long position or call options on ANTX as a result. In of 67 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.446) is normal, around the industry mean (26.681). P/E Ratio (0.000) is within average values for comparable stocks, (45.953). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.776). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (325.679).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ANTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology